They report that the Abdala vaccine has an efficacy of …

Cuba reported on Monday that its three-shot Abdala coronavirus vaccine has demonstrated 92.28% efficacy in Phase 3 clinical trials. BioCubaFarm, the laboratory that designed the vaccine which is set to become the first dose against the coronavirus to be created in Latin America.

“Abdala, a vaccine candidate from the Center for Genetic Engineering and Biotechnology, shows an efficacy of 92.28%, in his 3-dose regimen,” said the laboratory. in a Twitter message.

With these results, Abdala would be officially considered a vaccine against covid-19, since the efficacy requirements demanded by the World Health Organization establish a 50 percent efficacy for vaccine registration.. Cuban authorities have announced that they hope to apply to the regulatory authority in a few weeks for authorization to use the emergency vaccines, although vaccination has already started on the island with “the intervention study on the population”.

The announcement came just days after the government said another local vaccine, Sovereign II, showed 62% effectiveness.

Cuban President Miguel Díaz-Canel visited the Center for Genetic Engineering and Biotechnology (CIGB) to learn firsthand the details of Abdala’s effectiveness, as the president recently announced on his Twitter account. “Struck by two pandemics (covid-19 and blockade), our scientists from Finlay and CIGB, crossed all the obstacles and gave us two very effective vaccines: Soberana and Abdala”, wrote the person in charge.

The announcement comes at a time when the island is experiencing a strong outbreak of the disease. This Monday recorded one of its worst days in terms of positive cases with 1,561, while since the start of the pandemic, 169,365 infections and 1,170 deaths have been recorded.